CHAPTER 1. Industry Overview of Sickle Cell Anemia Drug Market
1.1. Definition and Scope
1.1.1. Definition of Sickle Cell Anemia Drug
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Sickle Cell Anemia Drug Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Sickle Cell Anemia Drug Market By Drug type
1.2.3. Sickle Cell Anemia Drug Market By Distribution channel
1.2.4. Sickle Cell Anemia Drug Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Sickle Cell Anemia Drug Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Sickle Cell Anemia Drug Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Sickle Cell Anemia Drug Market By Drug type
5.1. Introduction
5.2. Sickle Cell Anemia Drug Revenue By Drug type
5.2.1. Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast, By Drug type, 2020-2032
5.2.2. Hydroxyurea
5.2.2.1. Hydroxyurea Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Iron chelation therapy
5.2.3.1. Iron chelation therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Blood transfusion therapy
5.2.4.1. Blood transfusion therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Bone marrow transplant
5.2.5.1. Bone marrow transplant Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.6. Gene therapy
5.2.6.1. Gene therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Sickle Cell Anemia Drug Market By Distribution channel
6.1. Introduction
6.2. Sickle Cell Anemia Drug Revenue By Distribution channel
6.2.1. Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast, By Distribution channel, 2020-2032
6.2.2. Hospital pharmacies
6.2.2.1. Hospital pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Retail pharmacies
6.2.3.1. Retail pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Online pharmacies
6.2.4.1. Online pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Sickle Cell Anemia Drug Market By Country
7.1. North America Sickle Cell Anemia Drug Market Overview
7.2. U.S.
7.2.1. U.S. Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
7.2.2. U.S. Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
7.3. Canada
7.3.1. Canada Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
7.3.2. Canada Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Sickle Cell Anemia Drug Market By Country
8.1. Europe Sickle Cell Anemia Drug Market Overview
8.2. U.K.
8.2.1. U.K. Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
8.2.2. U.K. Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
8.3. Germany
8.3.1. Germany Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
8.3.2. Germany Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
8.4. France
8.4.1. France Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
8.4.2. France Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
8.5. Spain
8.5.1. Spain Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
8.5.2. Spain Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
8.6.2. Rest of Europe Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Sickle Cell Anemia Drug Market By Country
9.1. Asia Pacific Sickle Cell Anemia Drug Market Overview
9.2. China
9.2.1. China Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
9.2.2. China Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
9.3. Japan
9.3.1. Japan Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
9.3.2. Japan Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
9.4. India
9.4.1. India Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
9.4.2. India Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
9.5. Australia
9.5.1. Australia Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
9.5.2. Australia Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
9.6. South Korea
9.6.1. South Korea Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
9.6.2. South Korea Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
9.7.2. Rest of Asia-Pacific Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Sickle Cell Anemia Drug Market By Country
10.1. Latin America Sickle Cell Anemia Drug Market Overview
10.2. Brazil
10.2.1. Brazil Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
10.2.2. Brazil Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
10.3. Mexico
10.3.1. Mexico Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
10.3.2. Mexico Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
10.4.2. Rest of Latin America Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Sickle Cell Anemia Drug Market By Country
11.1. Middle East & Africa Sickle Cell Anemia Drug Market Overview
11.2. GCC
11.2.1. GCC Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
11.2.2. GCC Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
11.3. South Africa
11.3.1. South Africa Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
11.3.2. South Africa Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Drug type, 2020-2032
11.4.2. Rest of Middle East & Africa Sickle Cell Anemia Drug Revenue (USD Billion) and Forecast By Distribution channel, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Sickle Cell Anemia Drug Market
12.1. Sickle Cell Anemia Drug Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Sickle Cell Anemia Drug Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Novartis International AG
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Billion), 2022
13.1.3.2. Novartis International AG 2022 Sickle Cell Anemia Drug Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Global Blood Therapeutics Inc.
13.3. Emmaus Life Sciences Inc.
13.4. Bristol Myers Squibb
13.5. Bluebird Bio Inc.
13.6. Pfizer Inc.
13.7. Sanofi SA
13.8. Imara Inc.
13.9. Sangamo Therapeutics Inc.
13.10. Gamida Cell Ltd.
13.11. Intellia Therapeutics Inc.
13.12. Editas Medicine Inc.
The market size of sickle cell anemia drug was USD 1.2 Billion in 2022.
The CAGR of sickle cell anemia drug is 4% during the analysis period of 2023 to 2032.
The key players operating in the global market are including Novartis International AG, Global Blood Therapeutics Inc., Emmaus Life Sciences Inc., Bristol Myers Squibb, Bluebird Bio Inc., Pfizer Inc., Sanofi SA, Imara Inc., Sangamo Therapeutics Inc., Gamida Cell Ltd., Intellia Therapeutics Inc., and Editas Medicine Inc.
North America held the dominating position in sickle cell anemia drug industry during the analysis period of 2023 to 2032.
Asia-Pacific region exhibited fastest growing CAGR for market of sickle cell anemia drug during the analysis period of 2023 to 2032.
The current trends and dynamics in the sickle cell anemia drug industry include increasing prevalence of sickle cell anemia, growing awareness of the disease and its management, and advancements in technology for drug development.
The hydroxyurea drug type held the maximum share of the sickle cell anemia drug industry.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date